Humacyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2.12	2.04	-	-	1.57	1.26
Revenue Growth	159.29%	-	-	-	23.91%	-15.29%
Cost of Revenue	81.5	78.4	88.6	76.55	63.26	61.34
Gross Profit	-79.37	-76.37	-88.6	-76.55	-61.7	-60.08
Selling, General & Admin	31.08	31.07	25.8	20.39	22.88	21.13
Operating Expenses	31.08	31.07	25.8	20.39	22.88	21.13
Operating Income	-110.46	-107.44	-114.4	-96.94	-84.58	-81.21
Interest Expense	-10.3	-11.25	-9.28	-6.6	-6.2	-4.35
Interest & Investment Income	1.81	2.59	4.1	5.47	2.63	0.02
Other Non Operating Income (Expenses)	27.95	38.77	3.92	-0.26	0.42	0.06
EBT Excluding Unusual Items	-90.99	-77.34	-115.66	-98.33	-87.73	-85.48
Merger & Restructuring Charges	-0.7	-0.7	-	-	-	-0.05
Other Unusual Items	-5.05	37.2	-33.05	-12.44	75.77	59.06
Pretax Income	-96.74	-40.83	-148.7	-110.78	-11.97	-26.48
Net Income	-96.74	-40.83	-148.7	-110.78	-11.97	-26.48
Net Income to Common	-96.67	-40.83	-148.7	-110.78	-11.97	-26.48
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	194	158	118	103	103	40
Shares Outstanding (Diluted)	194	158	118	103	103	40
Shares Change	45.78%	33.49%	14.56%	0.36%	157.82%	593.25%
EPS (Basic)	-0.50	-0.26	-1.26	-1.07	-0.12	-0.66
EPS (Diluted)	-0.50	-0.26	-1.26	-1.07	-0.12	-0.66
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-97.56	-105.93	-99.69	-75.59	-72.18	-81.41
Free Cash Flow Per Share	-0.50	-0.67	-0.84	-0.73	-0.70	-2.04
Operating Margin	-5207.78%	-5271.69%	-	-	-5404.35%	-6429.77%
Profit Margin	-4557.66%	-2003.58%	-	-	-764.54%	-2096.36%
Free Cash Flow Margin	-4599.72%	-5197.55%	-	-	-4611.95%	-6445.76%
EBITDA	-103.23	-100.09	-107.21	-89.22	-76.37	-72.97
D&A For EBITDA	7.23	7.35	7.19	7.72	8.21	8.24
EBIT	-110.46	-107.44	-114.4	-96.94	-84.58	-81.21
Revenue as Reported	2.12	2.04	-	-	-	-

SEC Filings: 10-K · 10-Q